

# Marius C Hoener

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/722804/marius-c-hoener-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

91  
papers

5,428  
citations

42  
h-index

73  
g-index

105  
ext. papers

6,377  
ext. citations

5.5  
avg, IF

5.71  
L-index

| #  | Paper   | IF  | Citations |
|----|---|-----|-----------|
| 91 | Pharmacological characterization of 3,4-methylenedioxamphetamine (MDA) analogs and two amphetamine-based compounds: N,β-DEPEA and DPIA.. <i>European Neuropsychopharmacology</i> , <b>2022</b> , 59, 9-22 | 1.2 | 0         |
| 90 | Receptor Interaction Profiles of 4-Alkoxy-3,5-Dimethoxy-Phenethylamines (Mescaline Derivatives) and Related Amphetamines.. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 794254                    | 5.6 | 0         |
| 89 | TAAR1 Expression in Human Macrophages and Brain Tissue: A Potential Novel Facet of MS Neuroinflammation. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,                           | 6.3 | 2         |
| 88 | The Pharmacological Profile of Second Generation Pyrovalerone Cathinones and Related Cathinone Derivative. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,                         | 6.3 | 3         |
| 87 | Antisense oligonucleotide treatment rescues UBE3A expression and multiple phenotypes of an Angelman syndrome mouse model. <i>JCI Insight</i> , <b>2021</b> , 6,   | 9.9 | 5         |
| 86 | Secreted retrovirus-like GAG-domain-containing protein PEG10 is regulated by UBE3A and is involved in Angelman syndrome pathophysiology. <i>Cell Reports Medicine</i> , <b>2021</b> , 2, 100360           | 18  | 6         |
| 85 | Electrophysiological Phenotype in Angelman Syndrome Differs Between Genotypes. <i>Biological Psychiatry</i> , <b>2019</b> , 85, 752-759   | 7.9 | 33        |
| 84 | TAAR1 levels and sub-cellular distribution are cell line but not breast cancer subtype specific. <i>Histochemistry and Cell Biology</i> , <b>2019</b> , 152, 155-166                                      | 2.4 | 4         |
| 83 | Trace amine-associated receptor 1 agonism promotes wakefulness without impairment of cognition in Cynomolgus macaques. <i>Neuropsychopharmacology</i> , <b>2019</b> , 44, 1485-1493                       | 8.7 | 9         |
| 82 | Monoamine receptor interaction profiles of 4-aryl-substituted 2,5-dimethoxyphenethylamines (2C-BI derivatives). <i>European Journal of Pharmacology</i> , <b>2019</b> , 855, 103-111                      | 5.3 | 11        |
| 81 | Metabolites of the ring-substituted stimulants MDMA, methylone and MDPV differentially affect human monoaminergic systems. <i>Journal of Psychopharmacology</i> , <b>2019</b> , 33, 831-841               | 4.6 | 15        |
| 80 | Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: Implications for clinical LSD use. <i>Biochemical Pharmacology</i> , <b>2019</b> , 164, 129-138           | 6   | 8         |
| 79 | Pharmacological profiles of compounds in preworkout supplements ("boosters"). <i>European Journal of Pharmacology</i> , <b>2019</b> , 859, 172515   | 5.3 | 4         |
| 78 | Pharmacological characterization of the aminorex analogs 4-MAR, 4,4RDMAR, and 3,4-DMAR. <i>NeuroToxicology</i> , <b>2019</b> , 72, 95-100   | 4.4 | 8         |
| 77 | Receptor Interaction Profiles of 4-Alkoxy-Substituted 2,5-Dimethoxyphenethylamines and Related Amphetamines. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 1423                                    | 5.6 | 7         |
| 76 | Stereochemistry of phase-1 metabolites of mephedrone determines their effectiveness as releasers at the serotonin transporter. <i>Neuropharmacology</i> , <b>2019</b> , 148, 199-209                      | 5.5 | 11        |
| 75 | Activation of trace amine-associated receptor 1 attenuates schedule-induced polydipsia in rats. <i>Neuropharmacology</i> , <b>2019</b> , 144, 184-192   | 5.5 | 6         |

|    |   |      |     |
|----|---|------|-----|
| 74 | Pronounced Hyperactivity, Cognitive Dysfunctions, and BDNF Dysregulation in Dopamine Transporter Knock-out Rats. <i>Journal of Neuroscience</i> , <b>2018</b> , 38, 1959-1972                             | 6.6  | 82  |
| 73 | Role of trace amine-associated receptor 1 in nicotine's behavioral and neurochemical effects. <i>Neuropsychopharmacology</i> , <b>2018</b> , 43, 2435-2444  | 8.7  | 29  |
| 72 | Pharmacological profile of mephedrone analogs and related new psychoactive substances. <i>Neuropharmacology</i> , <b>2018</b> , 134, 4-12   | 5.5  | 54  |
| 71 | Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs). <i>Neuropharmacology</i> , <b>2018</b> , 134, 141-148   | 5.5  | 23  |
| 70 | Pharmacological profile of methylphenidate-based designer drugs. <i>Neuropharmacology</i> , <b>2018</b> , 134, 133-140  | 5.5  | 29  |
| 69 | The psychostimulant (±)-cis-4,4Rdimethylaminorex (4,4RDMAR) interacts with human plasmalemmal and vesicular monoamine transporters. <i>Neuropharmacology</i> , <b>2018</b> , 138, 282-291                 | 5.5  | 16  |
| 68 | Deletion of Trace Amine-Associated Receptor 1 Attenuates Behavioral Responses to Caffeine. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 35   | 5.6  | 6   |
| 67 | How Female Mice Attract Males: A Urinary Volatile Amine Activates a Trace Amine-Associated Receptor That Induces Male Sexual Interest. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 924            | 5.6  | 9   |
| 66 | Effects of the new psychoactive substances diclofensine, diphenidine, and methoxphenidine on monoaminergic systems. <i>European Journal of Pharmacology</i> , <b>2018</b> , 819, 242-247                  | 5.3  | 25  |
| 65 | Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome. <i>British Journal of Pharmacology</i> , <b>2018</b> , 175, 532-543  | 8.6  | 52  |
| 64 | Trace Amines and Their Receptors. <i>Pharmacological Reviews</i> , <b>2018</b> , 70, 549-620  | 22.5 | 135 |
| 63 | A partial trace amine-associated receptor 1 agonist exhibits properties consistent with a methamphetamine substitution treatment. <i>Addiction Biology</i> , <b>2017</b> , 22, 1246-1256                  | 4.6  | 32  |
| 62 | Trace Amine-Associated Receptor 1 Agonists as Narcolepsy Therapeutics. <i>Biological Psychiatry</i> , <b>2017</b> , 82, 623-633   | 7.9  | 31  |
| 61 | Interaction Between the Trace Amine-Associated Receptor 1 and the Dopamine D Receptor Controls Cocaine's Neurochemical Actions. <i>Scientific Reports</i> , <b>2017</b> , 7, 13901                        | 4.9  | 21  |
| 60 | Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges. <i>Pharmacology &amp; Therapeutics</i> , <b>2017</b> , 180, 161-180                                     | 13.9 | 103 |
| 59 | Trace Amine-Associated Receptor 1 Regulates Wakefulness and EEG Spectral Composition. <i>Neuropsychopharmacology</i> , <b>2017</b> , 42, 1305-1314  | 8.7  | 20  |
| 58 | The Trace Amine-Associated Receptor 1 Agonist RO5256390 Blocks Compulsive, Binge-like Eating in Rats. <i>Neuropsychopharmacology</i> , <b>2017</b> , 42, 1458-1470  | 8.7  | 47  |
| 57 | In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2016</b> , 357, 134-44 | 4.7  | 68  |

|    |  |     |     |
|----|--|-----|-----|
| 56 | Incretin-like effects of small molecule trace amine-associated receptor 1 agonists. <i>Molecular Metabolism</i> , <b>2016</b> , 5, 47-56   | 8.8 | 56  |
| 55 | Discovery and Characterization of 2-Aminooxazolines as Highly Potent, Selective, and Orally Active TAAR1 Agonists. <i>ACS Medicinal Chemistry Letters</i> , <b>2016</b> , 7, 192-7   | 4.3 | 24  |
| 54 | Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. <i>European Neuropsychopharmacology</i> , <b>2016</b> , 26, 1327-37   | 1.2 | 124 |
| 53 | A UGT2B10 splicing polymorphism common in african populations may greatly increase drug exposure. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2015</b> , 352, 358-67   | 4.7 | 38  |
| 52 | Selective activation of the trace amine-associated receptor 1 decreases cocaine's reinforcing efficacy and prevents cocaine-induced changes in brain reward thresholds. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2015</b> , 63, 70-5 | 5.5 | 43  |
| 51 | Pharmacological profile of novel psychoactive benzofurans. <i>British Journal of Pharmacology</i> , <b>2015</b> , 172, 3412-25   | 8.6 | 80  |
| 50 | TAAR1 Modulates Cortical Glutamate NMDA Receptor Function. <i>Neuropsychopharmacology</i> , <b>2015</b> , 40, 2217-27  | 8.7 | 74  |
| 49 | Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). <i>Neuropharmacology</i> , <b>2015</b> , 99, 546-53  | 5.5 | 113 |
| 48 | Trace amine-associated receptor 1 activation silences GSK3 $\beta$ signaling of TAAR1 and D2R heteromers. <i>European Neuropsychopharmacology</i> , <b>2015</b> , 25, 2049-61  | 1.2 | 74  |
| 47 | The trace amine-associated receptor 1 modulates methamphetamine's neurochemical and behavioral effects. <i>Frontiers in Neuroscience</i> , <b>2015</b> , 9, 39   | 5.1 | 49  |
| 46 | Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones. <i>European Neuropsychopharmacology</i> , <b>2015</b> , 25, 365-76  | 1.2 | 129 |
| 45 | Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives. <i>Biochemical Pharmacology</i> , <b>2014</b> , 88, 237-44   | 6   | 69  |
| 44 | Monoamine transporter and receptor interaction profiles of a new series of designer cathinones. <i>Neuropharmacology</i> , <b>2014</b> , 79, 152-60  | 5.5 | 143 |
| 43 | Activation of the trace amine-associated receptor 1 prevents relapse to cocaine seeking. <i>Neuropsychopharmacology</i> , <b>2014</b> , 39, 2299-308   | 8.7 | 61  |
| 42 | P.1.h.027 Dopamine transporter knockout rats: new experimental model in behavioral psychopharmacology research. <i>European Neuropsychopharmacology</i> , <b>2014</b> , 24, S285   | 1.2 |     |
| 41 | Taar1-mediated modulation of presynaptic dopaminergic neurotransmission: role of D2 dopamine autoreceptors. <i>Neuropharmacology</i> , <b>2014</b> , 81, 283-91  | 5.5 | 98  |
| 40 | TAAR1-dependent effects of apomorphine in mice. <i>International Journal of Neuropsychopharmacology</i> , <b>2014</b> , 17, 1683-93  | 5.8 | 30  |
| 39 | In vitro pharmacology of pipradrol derivatives, 3,4-methylenedioxypyrovalerone, and naphyrone (1145.3). <i>FASEB Journal</i> , <b>2014</b> , 28, 1145.3  | 0.9 |     |

|    |  |      |     |
|----|--|------|-----|
| 38 | Pharmacological characterization of designer cathinones in vitro. <i>British Journal of Pharmacology</i> , <b>2013</b> , 168, 458-70   | 8.6  | 497 |
| 37 | A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. <i>Molecular Psychiatry</i> , <b>2013</b> , 18, 543-56  | 15.1 | 157 |
| 36 | The impact of Bdnf gene deficiency to the memory impairment and brain pathology of APPswe/PS1dE9 mouse model of Alzheimer's disease. <i>PLoS ONE</i> , <b>2013</b> , 8, e68722   | 3.7  | 42  |
| 35 | The antidepressant-like effects of glutamatergic drugs ketamine and AMPA receptor potentiator LY 451646 are preserved in bdnf+/? heterozygous null mice. <i>Neuropharmacology</i> , <b>2012</b> , 62, 391-7  | 5.5  | 76  |
| 34 | Optimisation of imidazole compounds as selective TAAR1 agonists: discovery of RO5073012. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2012</b> , 22, 5244-8  | 2.9  | 39  |
| 33 | Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics. <i>Biological Psychiatry</i> , <b>2012</b> , 72, 934-42  | 7.9  | 115 |
| 32 | Trace amine associated receptor 1 signaling in activated lymphocytes. <i>Journal of NeuroImmune Pharmacology</i> , <b>2012</b> , 7, 866-76   | 6.9  | 56  |
| 31 | Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study. <i>PLoS ONE</i> , <b>2012</b> , 7, e36476  | 3.7  | 122 |
| 30 | Brain-specific overexpression of trace amine-associated receptor 1 alters monoaminergic neurotransmission and decreases sensitivity to amphetamine. <i>Neuropsychopharmacology</i> , <b>2012</b> , 37, 2580-92   | 8.7  | 74  |
| 29 | Effects of the $\alpha$ 2-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2012</b> , 340, 286-94 | 4.7  | 56  |
| 28 | Acetylcholinesterase inhibitors rapidly activate Trk neurotrophin receptors in the mouse hippocampus. <i>Neuropharmacology</i> , <b>2011</b> , 61, 1291-6  | 5.5  | 42  |
| 27 | The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans. <i>Clinical Pharmacology and Therapeutics</i> , <b>2011</b> , 90, 246-55  | 6.1  | 113 |
| 26 | Selective antagonists of mouse trace amine-associated receptor 1 (mTAAR1): discovery of EPPTB (RO5212773). <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2011</b> , 21, 1227-31   | 2.9  | 46  |
| 25 | G protein-coupled receptor transmembrane binding pockets and their applications in GPCR research and drug discovery: a survey. <i>Current Topics in Medicinal Chemistry</i> , <b>2011</b> , 11, 1902-24  | 3    | 17  |
| 24 | TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 8485-90             | 11.5 | 225 |
| 23 | Darkness reduces BDNF expression in the visual cortex and induces repressive chromatin remodeling at the BDNF gene in both hippocampus and visual cortex. <i>Cellular and Molecular Neurobiology</i> , <b>2010</b> , 30, 1117-23                         | 4.6  | 38  |
| 22 | A functional NR4A nuclear receptor DNA-binding domain is required for organ development in <i>Caenorhabditis elegans</i> . <i>Genesis</i> , <b>2010</b> , 48, 485-91   | 1.9  | 10  |
| 21 | The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 20081-6        | 11.5 | 147 |

|    |   |      |     |
|----|---|------|-----|
| 20 | P.l.c.038 Modulation of dopaminergic activity in the mesolimbic system by trace amine-associated receptor 1 (TAAR1) modification. <i>European Neuropsychopharmacology</i> , <b>2009</b> , 19, S273  | 1.2  | 1   |
| 19 | The <i>Caenorhabditis elegans</i> NR4A nuclear receptor is required for spermatheca morphogenesis. <i>Developmental Biology</i> , <b>2008</b> , 313, 767-86   | 3.1  | 27  |
| 18 | Trace amine-associated receptor 1 modulates dopaminergic activity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2008</b> , 324, 948-56   | 4.7  | 228 |
| 17 | An automated system for the analysis of G protein-coupled receptor transmembrane binding pockets: alignment, receptor-based pharmacophores, and their application. <i>Journal of Chemical Information and Modeling</i> , <b>2005</b> , 45, 1324-36              | 6.1  | 53  |
| 16 | Trace amine-associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors. <i>Genomics</i> , <b>2005</b> , 85, 372-85   | 4.3  | 205 |
| 15 | A renaissance in trace amines inspired by a novel GPCR family. <i>Trends in Pharmacological Sciences</i> , <b>2005</b> , 26, 274-81   | 13.2 | 212 |
| 14 | Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in <i>Caenorhabditis elegans</i> . <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 42655-42668                      | 5.4  | 206 |
| 13 | <i>Caenorhabditis elegans</i> MPP+ model of Parkinson's disease for high-throughput drug screenings. <i>Neurodegenerative Diseases</i> , <b>2004</b> , 1, 175-83  | 2.3  | 138 |
| 12 | Geldanamycin restores a defective heat shock response in vivo. <i>Journal of Biological Chemistry</i> , <b>2001</b> , 276, 45160-7  | 5.4  | 51  |
| 11 | Role played by sodium in activity-dependent secretion of neurotrophins - revisited. <i>European Journal of Neuroscience</i> , <b>2000</b> , 12, 3096-106  | 3.5  | 13  |
| 10 | Are there differences between the secretion characteristics of NGF and BDNF? Implications for the modulatory role of neurotrophins in activity-dependent neuronal plasticity. <i>Microscopy Research and Technique</i> , <b>1999</b> , 45, 262-75               | 2.8  | 102 |
| 9  | Partial cortical devascularization results in elevations of cortical nerve growth factor and increases nerve growth factor protein within basal forebrain cholinergic neurons. <i>Neuroscience</i> , <b>1998</b> , 83, 1003-11                                  | 3.9  | 6   |
| 8  | Reversible sedimentation and masking of nerve growth factor (NGF) antigen by high molecular weight fractions from rat brain. <i>Brain Research</i> , <b>1997</b> , 772, 1-8   | 3.7  | 7   |
| 7  | Effects of sodium chloride, Triton X-100, and alkaline pH on the measurable contents and sedimentability of the nerve growth factor (NGF) antigen in adult rat hippocampal tissue extracts. <i>Journal of Neuroscience Research</i> , <b>1997</b> , 49, 508-514 | 4.4  | 10  |
| 6  | Nerve growth factor (NGF) content in adult rat brain tissues is several-fold higher than generally reported and is largely associated with sedimentable fractions. <i>Brain Research</i> , <b>1996</b> , 728, 47-56   | 3.7  | 28  |
| 5  | Conversion of the amphiphilic 115 kDa Form of Glycosyl-Phosphatidylinositol-specific Phospholipase D to an active, hydrophilic 47 kDa Form <b>1994</b> , 71-78  |      | 1   |
| 4  | Glycosyl-phosphatidylinositol-specific phospholipase D. Interaction with and stimulation by apolipoprotein A-I. <i>FEBS Letters</i> , <b>1993</b> , 327, 203-6  | 3.8  | 20  |
| 3  | Phosphatidylinositol Glycan-Anchor-Specific Phospholipase D from Mammalian Brain. <i>Methods in Neurosciences</i> , <b>1993</b> , 3-13  |      | 1   |

- 2 Phosphatidylinositol-glycan-specific phospholipase D is an amphiphilic glycoprotein that in serum is associated with high-density lipoproteins. *FEBS Journal*, **1992**, 206, 747-57 75
- 1 Isolation and characterization of a phosphatidylinositol-glycan-anchor-specific phospholipase D from bovine brain. *FEBS Journal*, **1990**, 190, 593-601 51